Publication Year

Thompson CM, Kirman CR, Proctor DM, Suh M, Hays SM, Haws LC, Harris MA. 2013. A chronic oral reference dose for hexavalent chromium. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Urban JD, Carakostas MC, Brusick, DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient? Food Chem Toxicol 51:386-390.

Racz L, Baker PA, Duckworth KL, Heline TR, Woodall BD. 2013. Environmental planning while deployed: Mission hindrance or enhancement? Joint Force Quarterly 70:30–33.

Flory J, Kanel SR, Racz L, Impellitteri CA, Rendahandi GS, Goltz MN. 2013. Influence of pH on the transport of silver nanoparticles in saturated porous media: laboratory experiments and modeling. J Nanopart Res 15(3):2–11.

Fryzek J, Pastula S, Jiang X, Garabrant DH. 2013. Childhood cancer incidence in Pennsylvania counties in relation to living in counties with hydraulic fracturing sites. J Occup Environ Med 55(7):796–801.

Fryzek J, Pastula S, Jiang X, Garabrant DH. 2013. Response to Goldstein et al. J Occup Environ Med 55(11):1378.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Gaylor DW, Tachovsky JA, Perry C, Carakostas MC, Haws LC. 2013. Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. J Appl Toxicol 33(12):1395-1406.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. 2013. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at the Society of Toxicology’s 52nd Annual Meeting, March 10-14, San Antonio, TX.

Covington TR, Ruark CD, Yu KO, Gearhart JM. Human lethality predictions from exposure to VX using a physiologically-based pharmacokinetic-pharmacodynamic model. Poster presented at the Society of Toxicology Annual Meeting, San Antonio, TX, March 2013.

Patterson J, Maier A, Kohrman-Vincent M, Dourson ML. 2013. Peer consultation on relationship between PAC profile and toxicity of petroleum substances. Regul Toxicol Pharmacol 67:S86–S93.

Belova A, Narayan T, Brown L, Haskell J, Bozeman S, Lamb J. A framework to assess aflatoxin public health impacts in developing countries with application to Nigeria and Tanzania. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Brown L, Lynch M, Post E, Belova A. Determine a concentration response relationship suitable for estimating adult benefits of reduced lead exposure. Presentation to Society for Risk Analysis, Baltimore, MD, 2013.

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47:94–103.

Sterner TR, Ruark CD, Covington TR, Yu KO, Gearhart JM. 2013. A physiologically based pharmacokinetic model for theoxime TMB-4: Simulation of rodent and human data. Arch Toxicol 87:661–680.

Hinerman JM, Dignam JD, Mueser T. 2012. A model of the bacteriophage T4 59 helicase assembly protein:32 single stranded DNA binding protein binary complex and analysis of interaction with Pseudo-Y junction DNA. J Biol Chem 287(22):8608–8617.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271:299–308.